Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. SWS Hemodialysis Care Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 12.98%.
SWS Hemodialysis Care Co (SHSE:688410) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
(1) Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SWS Hemodialysis Care Co (SHSE:688410) has a ROCE % of 12.98% as of Mar. 2026.
Is SWS Hemodialysis Care Co's ROCE % too high?
SWS Hemodialysis Care Co's current ROCE % is 12.98%. The Medical Devices & Instruments industry median ROCE % is 2.22. SWS Hemodialysis Care Co's value of 12.98% is 484.7% above this industry median. Overall, SWS Hemodialysis Care Co has a GF Score™ of 88/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SWS Hemodialysis Care Co's ROCE % compare to ISRG and BDX?
SWS Hemodialysis Care Co's ROCE % of 12.98% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.22. SWS Hemodialysis Care Co's value of 12.98% is 484.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.22, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SWS Hemodialysis Care Co's current ROCE % of 12.98% is 484.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SWS Hemodialysis Care Co's current ROCE % is 12.98%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SWS Hemodialysis Care Co stock overvalued right now?
Based on GuruFocus' analysis, SWS Hemodialysis Care Co (SHSE:688410) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥15.44, compared to a current price of ¥10.59 — trading 31.4% below its estimated fair value. The current ROCE % is 12.98% and 484.7% above the Medical Devices & Instruments industry median of 2.22. SWS Hemodialysis Care Co's overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For SWS Hemodialysis Care Co (SHSE:688410), the current ROCE % is 12.98% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SWS Hemodialysis Care Co (SHSE:688410) Overvalued in 2026?
Based on GuruFocus' analysis, SWS Hemodialysis Care Co stock appears to be undervalued.
The current stock price of ¥10.59 is trading 31.4% below its estimated GF Value™ of ¥15.44.
GuruFocus considers SWS Hemodialysis Care Co to be Significantly Undervalued.
Key valuation signals for SHSE:688410:
ROCE %: 12.98%
GF Value™: ¥15.44 vs. price of ¥10.59 (31.4% below fair value)
Industry Position: 484.7% above the Medical Devices & Instruments median
No single metric tells the full story. See the SHSE:688410 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SWS Hemodialysis Care Co Ltd along with its subsidiaries is engaged in the field of blood purification. Its focused on patients welfare and ensuring the delivery of safe and effective products and services. The group operates through four segments: Blood Purification Equipment, Blood Purification Consumables, advanced Hemodialysis Management System, and Chain Dialysis centers. The organization is delivering medical solutions for patients with chronic kidney disease (CKD). Its products include Blood Purification Equipment Dialysis, Disposables Dialysis Center, Intelligent Management System, and Chain Dialysis centers. SWS is committed to enhancing patient wellness by prioritizing care through advanced integrated blood purification technologies.
88GF Score
Get the complete analysis for SHSE:688410
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688410 has been successfully added to your 
